Problem Solving Roundtable Discussions

These are informal, moderated discussions with brainstorming and interactive problem solving, allowing participants from diverse backgrounds to exchange ideas and experiences and develop future collaborations around a focused topic. Details on the topics and moderators are below.

BISPECIFIC ANTIBODY DESIGN

TUESDAY, AUGUST 20 , 4:00 – 5:00 PM

Novel Scaffolds as Multi-Functional Drugs

Moderator: H. Kaspar Binz, PhD, CEO Binz Biotech Consulting

• What are the opportunities for using non-immunoglobulin binding domains?
• What challenges would one expect for novel scaffolds?
• Which benefits are expected when using novel scaffolds?
• Which approaches are enabled by novel scaffolds and which ones remain impossible?

Antibody Derivatives with Prodrug Functionality

Moderator: Ulrich Brinkmann, PhD, Expert Scientist, Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, FRG

• Academic/exotic playground vs next generation platforms?
• What for alternatives?
• Pro/con of different in/activation approaches?

BISPECIFIC CASE STUDIES & CLINICAL RELEVANCE

WEDNESDAY, AUGUST 21, 5:00 – 6:00 PM

PK and Immunogenicity Analytical Strategy to Support Bispecific Antibody Clinical Development

Moderator: Kate Peng, PhD, Group Leader/Senior Scientist, BioAnalytical Sciences, Genentech

• PK method development considerations
• Immunogenicity assessment strategy

Safety of Bispecifics Based on CD3 Targeting on T Cells

Moderator: Rakesh Dixit, PhD, DABT, President & CEO, Bionavigen

• Advantages of CD3-based Bispecifics, meeting the deficiencies of the BITE molecules
• Discussion on CD3 bispecific formats? Target selection?
• Safety challenges of CD-3 bispecifics: Target related or format based?
• Risk mitigation through smart engineering approaches